Neurodegenerative disorders

Combination therapy shows promising efficacy against ALS decline

A combination of sodium phenylbutyrate and taurursodiol has shown tantalising preliminary results against functional decline in patients with amyotrophic lateral sclerosis (ALS). In a 24-week phase 2 randomised controlled trial, US researchers showed that the combination – also known as tauroursodeoxycholic acid – was associated with a 25% drug-associated slowing of the rate of functional ...

Already a member?

Login to keep reading.

© 2021 the limbic